Dyax reports interim analysis data of Phase 2 ecallantide trial

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

CDSCO Moves to Online Submission for CGTP Trial Applications

As part of its continued efforts to streamline operations...

Adaptive RCTs: Transforming Clinical Trials for Efficiency

Randomised controlled trials (RCTs) have long been the gold...

Big Data Integration Transforming Clinical Trials

In the years that have gone by, the big...

Clinical Trial Supplies Market Worth $8.18 Billion by 2030

The market for clinical trial supplies is about to...

Dyax has reported interim analysis results of Phase 2 trial of ecallantide for acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema.

Based on the data from interim analysis the company decided to discontinue the double-blind, placebo-controlled study.

The randomized study was designed to evaluate the efficacy and safety of ecallantide (10, 30, or 60mg subcutaneous doses) compared to placebo.

The proportion of patients meeting a set of criteria indicating eligibility for discharge from the emergency department within six hours after study drug administration was the primary endpoint of the dose-ranging study.

Dyax president and chief executive officer Gustav Christensen said the company will continue to actively investigate novel therapeutic approaches for angioedema disorders, including next generation therapies and testing.

“These results, while unanticipated, provide us with further evidence and understanding of the biology of angioedema, supporting our efforts to address these disorders and to remain at the forefront of therapeutic innovation,” Christensen added.

The study was determined to be poorly powered to detect a statistically significant difference between ecallantide and placebo as the observed response rate to placebo was substantially higher than originally anticipated and the enrolled population does not appear to reproduce the high morbidity described in previous medical literature.

Latest stories

Related stories

CDSCO Moves to Online Submission for CGTP Trial Applications

As part of its continued efforts to streamline operations...

Adaptive RCTs: Transforming Clinical Trials for Efficiency

Randomised controlled trials (RCTs) have long been the gold...

Big Data Integration Transforming Clinical Trials

In the years that have gone by, the big...

Clinical Trial Supplies Market Worth $8.18 Billion by 2030

The market for clinical trial supplies is about to...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back